Profound Medical Corp. Common Stock
PROFProfound Medical Corp. is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of various urological conditions. It specializes in minimally invasive, image-guided treatments, notably through its flagship platform for transurethral ultrasound-guided therapy. The company aims to provide effective and less invasive procedures that improve patient outcomes in areas such as benign prostatic hyperplasia (BPH).
Company News
Dr. Pejman Ghanouni from Stanford Medicine received a Cum Laude award at RSNA 2025 for presenting results from the CAPTAIN trial, comparing MRI-guided transurethral ultrasound ablation (TULSA) with robotic radical prostatectomy for prostate cancer treatment.
Profound Medical reported strong preliminary Q4 2024 revenue growth of 105-110% year-over-year, driven by increased adoption of its TULSA-PRO technology. The company will transition to reporting under U.S. GAAP and filing with the SEC on domestic forms to better serve its primarily U.S.-based investor base.
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
PROF earnings call for the period ending June 30, 2022.
